- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02309710
Male Circumcision (MC) Using the ShangRing™ Device in Malawi
Prospective Study of Male Circumcision Using the ShangRing Device in Routine Clinical Settings in Malawi
Study Overview
Detailed Description
Although voluntary medical male circumcision (VMMC) was adopted as a prevention strategy in 2011, MMC prevalence in Malawi is low with estimates between 2 and 20%. The 5-year national VMMC target for Malawi is 80% of men ages 15 - 49, or more than two million procedures. Since 2011, only 42,700 VMMCs have been done for HIV prevention, about 2% of the target. Of the 29 healthcare districts in Malawi, only a minority are supported by non-governmental (NGO) and U.S. government-funded VMMC programs. Major obstacles include few VMMC service-delivery points; few trained service providers; poor availability of prepackaged disposable VMMC kits requiring re-use of instruments and supplies; few organized campaigns or community mobilization programs; and drop-in services only.
Scale-up of adult MMC services in Malawi could be accelerated by the availability of simplified, bloodless methods. Methods of MMC using devices may also increase safety, efficiency and acceptability. Although many devices are available and widely used for infant circumcision, fewer devices exist for use in adult male circumcision and there are limited data on device use in adults. Small-scale safety studies, randomized controlled trials (RCTs), and field demonstration studies are required before the safety, effectiveness, acceptability, and feasibility of any device is assured.
Several devices have recently been developed that have the potential to simplify and shorten both training time and surgical duration by eliminating the need for suturing and hemostasis as well as allow for task-shifting to lower-level cadres of healthcare providers (i.e. non-physician), thereby reducing the strain on healthcare systems by having more healthcare workers available to provide MMC services. One such device is the ShangRing.
In the WHO framework, smaller bridging studies are recommended to address additional questions about particular sub-populations and specific conditions of use (WHO 2011). This research study will assess the safety and acceptability of the ShangRing within the context of routine service delivery in Namitete, Malawi. The investigators will enroll 500 HIV-uninfected adult men aged 18 to 49 years voluntarily seeking medical male circumcision. The men will be scheduled for two follow-up visits at 7 and 42 days after ShangRing placement for device removal and a healing check, respectively. Results from this study will inform the Malawi Ministry of Health (MOH) as it decides on the integration of MMC devices into its national VMMC program.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Lilongwe, Malawi
- Christian Health Association of Malawi
-
Namitete, Malawi
- St Gabriel's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be aged 18 to 49 years;
- Must be HIV-uninfected per same-day routine HIV testing and counseling (HTC) at the clinic;
- Must be uncircumcised (on examination);
- Must be in good general health, at the discretion of the clinician;
- Must be free of genital ulcerations or other visible signs of sexually transmitted infections(STI) on examination;
- Must be able to understand study procedures, and agree to abide by them including the follow-up visit schedule;
- Must be able to communicate in English or Chichewa;
- Must freely consent to participate in the study, be available for follow-up visits, and sign a written informed consent form (ICF); and
- Must provide full contact information including cell phone number, address, and other locator information
Exclusion Criteria:
- Has an anatomic abnormality (e.g. phimosis or hypospadias) that contraindicates ShangRing MMC;
- Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;
- Has a self-reported medical condition that would be a contraindication for elective surgery, e.g. hemophilia, extreme obesity, poorly controlled diabetes, sickle cell anemia;
- Has a self-reported allergy or sensitivity to lidocaine or other local anesthesia; or
- Is not available to be circumcised on the same day as screening.
Study Plan
How is the study designed?
Design Details
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ShangRing
ShangRing administered to men seeking medical male circumcision
|
ShangRing administered to males seeking medical male circumcision
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of men with moderate and severe adverse events will be tabulated with 95% confidence intervals
Time Frame: up to 42 days following circumcision procedure
|
up to 42 days following circumcision procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of men ineligible for MMC with ShangRing
Time Frame: up to four months
|
The proportion and 95% confidence interval (CI) of men who did not receive ShangRing circumcision because of inability to find an appropriate size will be reported
|
up to four months
|
Percentage distribution of overall satisfaction for study participants
Time Frame: at Day 42 visit
|
Study participants will be interviewed using a standardized questionnaire with items on overall satisfaction with the ShangRing procedure.
|
at Day 42 visit
|
Percentage preference for ShangRing procedure among study MC providers
Time Frame: an expected average of one month after study initiation
|
Study circumcision providers will complete the first questionnaire after receiving training and completing 20 circumcision and device removal procedures.
Providers will be interviewed using a standardized questionnaire that includes items on preference for ShangRing.
|
an expected average of one month after study initiation
|
Complete Healing at final follow up visit
Time Frame: up to 42 days
|
Percentage of men with complete healing at 42 days for all study participants
|
up to 42 days
|
Percentage preference for ShangRing procedure among study MC providers
Time Frame: An expected average of six months after study initiation
|
Providers will complete a second questionnaire at the end of the study after all follow-up visits are completed.
Study circumcision providers will be interviewed using a standardized questionnaire that includes items on preference for ShangRing.
|
An expected average of six months after study initiation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Feldblum, Ph.D., FHI 360
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 595330-3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Circumcision
-
ProgressusUnknownCircumcision, Male | Circumcision Status: Circumcised, Uncircumcised
-
University of North Carolina, Chapel HillBill and Melinda Gates Foundation; FHI 360; Impact Research & Development OrganizationCompletedVoluntary Medical Male Circumcision | Circumcision AdultKenya
-
Weill Medical College of Cornell UniversityBill and Melinda Gates FoundationCompleted
-
King Saud UniversityUnknownCircumcision, MaleSaudi Arabia
-
Medical University of South CarolinaCompleted
-
Simunye Primary Health CareCompleted
-
Kocatepe UniversityCompleted
-
FHI 360Weill Medical College of Cornell University; Bill and Melinda Gates Foundation and other collaboratorsCompletedMale CircumcisionKenya, Zambia
-
ProgressusUnknownMale | CircumcisionZambia
Clinical Trials on ShangRing
-
FHI 360Bill and Melinda Gates Foundation; Ministry of Health, ZambiaCompleted
-
JhpiegoColumbia University; Centers for Disease Control and Prevention; Ministry of...WithdrawnCircumcision, MaleMozambique
-
IntraHealth InternationalCenters for Disease Control and Prevention; World Health Organization; Jhpiego; Ministry of Health, Tanzania and other collaboratorsCompletedDeformity | Penile Infection | Penile Haematoma | Penile BleedingTanzania
-
Weill Medical College of Cornell UniversityJohns Hopkins University; Bill and Melinda Gates Foundation; George Washington... and other collaboratorsCompletedCircumcisionUganda, Kenya, Tanzania